Lanadelumab Reduces Pediatric HAE Attacks by 95%
Attack frequency among pediatric hereditary angioedema patients fell by 95% following treatment with lanadelumab, according to a real-world analysis presented in Phoenix, Arizona, HCPLive reported.
- Pediatric attack rates dropped by 95% after lanadelumab initiation.
- Patients experienced roughly one attack every two months during the baseline period.
- Every evaluated patient reported attacks resolving without requiring on-demand therapy after treatment.
Patients mostly identified as male and White
The analysis examined patients where approximately 40% fell into the 6 to 12 years age bracket and approximately 60% were aged 12 to 18 years, HCPLive reported. Most participants were male, presented with type 1 HAE, and identified as White.
Patients started lanadelumab at various points throughout their disease progression. This included initiations immediately following diagnosis, subsequent to a hospitalization, or right after experiencing their first symptom onset.
During the baseline period before receiving the prophylactic treatment, patients experienced roughly one attack every two months. These attacks frequently targeted the abdomen or peripheral regions, impacting the hands and feet.
Lanadelumab reduced attack frequency by 95%
Some patients also suffered from facial, genital, and airway attacks prior to starting the medication. Most of these episodes required on-demand therapy, and few instances resolved without active medical intervention.
Following lanadelumab initiation, attack frequency fell by 95%. “So basically, [participants had] no attacks,” Lumry said, adding that patients experienced perhaps one attack a year at the very most.
“[Participants had] no attacks. Maybe 1 attack a year at [the] very most,” Lumry said.
After treatment initiation, 100% of patients reported that their subsequent attacks resolved entirely without the need for on-demand therapy.
Real-world findings align with phase 3 SPRING study results
These real-world findings align closely with results generated during the phase 3 SPRING study. That open-label, multicenter trial evaluated lanadelumab across 21 patients aged 2 to under 12 years old, as detailed in the Journal of Allergy and Clinical Immunology: In Practice.
In the SPRING trial, the mean attack rate decreased by 94.8% from baseline, shifting from 1.84 down to 0.08 attacks per month. 76.2% of patients remained completely attack-free throughout the entire 52-week treatment period.
Researchers observed no serious treatment-emergent adverse events during the study. No participants discontinued treatment due to adverse events, with injection site pain standing out as the most common treatment-emergent adverse event.
Data presented at American College of Allergy, Asthma and Immunology meeting
The data findings were presented at the American College of Allergy, Asthma and Immunology 2026 Annual Scientific Meeting held from November 12 to 16, 2026, in Phoenix, Arizona, HCPLive reported.
These real-world metrics build upon previous regulatory decisions. The US Food and Drug Administration approved Takeda’s Takhzyro on February 3, 2023, to prevent hereditary angioedema attacks in children 2 years of age and older.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.